Background: Regional radiation therapy (RT) has been shown to reduce the risk of regional recurrence with node-positive cutaneous melanoma. However, risk factors for regional recurrence, especially in the era of sentinel lymph node biopsy (SLNB), are less clear. Our goals were to identify risk factors associated with regional recurrence and to determine whether a radiosensitivity index (RSI) gene expression signature (GES) could identify patients who experience a survival benefit with regional RT. Methods: A single-institution, Institutional Review Board-approved study was performed including 410 patients treated with either SLNB with or without completion lymph node dissection (LND; n=270) or therapeutic LND (n=91). Postoperative regional RT was delivered to the involved nodal basin in 83 cases (20.2%), to a median dose of 54 Gy (range, 30-60 Gy) in 27 fractions (range, 5-30). Primary outcomes were regional control and overall survival by RSI GES status. Results: Median follow-up was 69 months (range, 13-180). Postoperative regional RT was associated with a reduced risk of regional recurrence among all patients on univariate (5-year estimate: 95.0% vs 83.3%; P=.036) and multivariate analysis (hazard ratio[HR], 0.15; 95% CI, 0.05-0.43; P<.001). Among higher-risk subgroups, regional RT was associated with a lower risk of regional recurrence among patients with clinically detected lymph nodes (n=175; 5-year regional control: 94.1% vs 69.5%; P=.003) and extracapsular extension (ECE) present (n=138; 5-year regional control: 96.7% vs 62.2%; P<.001). Among a subset of radiated patients with gene expression data available, a low RSI GES (radiosensitive) tumor status was associated with improved survival compared with a high RSI GES (5-year: 75% vs 0%; HR, 10.68; 95% CI, 1.24-92.14). Conclusions: Regional RT was associated with a reduced risk of regional recurrence among patients with ECE and clinically detected nodal disease. Gene expression data show promise for better predicting radiocurable patients in the future. In the era of increasingly effective systemic therapies, the value of improved regional control potentially takes on greater significance.
Background: Regional radiation therapy (RT) has been shown to reduce the risk of regional recurrence with node-positive cutaneous melanoma. However, risk factors for regional recurrence, especially in the era of sentinel lymph node biopsy (SLNB), are less clear. Our goals were to identify risk factors associated with regional recurrence and to determine whether a radiosensitivity index (RSI) gene expression signature (GES) could identify patients who experience a survival benefit with regional RT. Methods: A single-institution, Institutional Review Board-approved study was performed including 410 patients treated with either SLNB with or without completion lymph node dissection (LND; n=270) or therapeutic LND (n=91). Postoperative regional RT was delivered to the involved nodal basin in 83 cases (20.2%), to a median dose of 54 Gy (range, 30-60 Gy) in 27 fractions (range, 5-30). Primary outcomes were regional control and overall survival by RSI GES status. Results: Median follow-up was 69 months (range, 13-180). Postoperative regional RT was associated with a reduced risk of regional recurrence among all patients on univariate (5-year estimate: 95.0% vs 83.3%; P=.036) and multivariate analysis (hazard ratio[HR], 0.15; 95% CI, 0.05-0.43; P<.001). Among higher-risk subgroups, regional RT was associated with a lower risk of regional recurrence among patients with clinically detected lymph nodes (n=175; 5-year regional control: 94.1% vs 69.5%; P=.003) and extracapsular extension (ECE) present (n=138; 5-year regional control: 96.7% vs 62.2%; P<.001). Among a subset of radiatedpatients with gene expression data available, a low RSI GES (radiosensitive) tumor status was associated with improved survival compared with a high RSI GES (5-year: 75% vs 0%; HR, 10.68; 95% CI, 1.24-92.14). Conclusions: Regional RT was associated with a reduced risk of regional recurrence among patients with ECE and clinically detected nodal disease. Gene expression data show promise for better predicting radiocurable patients in the future. In the era of increasingly effective systemic therapies, the value of improved regional control potentially takes on greater significance.
Authors: Jeong Il Yu; Won Park; Seung Jae Huh; Doo Ho Choi; Young Hyuk Lim; Jin Suk Ahn; Jung Hyun Yang; Suk Jin Nam Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-16 Impact factor: 7.038
Authors: Michael A Henderson; Bryan H Burmeister; Jill Ainslie; Richard Fisher; Juliana Di Iulio; B Mark Smithers; Angela Hong; Kerwin Shannon; Richard A Scolyer; Scott Carruthers; Brendon J Coventry; Scott Babington; Joao Duprat; Harald J Hoekstra; John F Thompson Journal: Lancet Oncol Date: 2015-07-20 Impact factor: 41.316
Authors: K K Ang; L J Peters; R S Weber; W H Morrison; R A Frankenthaler; A S Garden; H Goepfert; C S Ha; R M Byers Journal: Int J Radiat Oncol Biol Phys Date: 1994-11-15 Impact factor: 7.038
Authors: Steven A Eschrich; William J Fulp; Yudi Pawitan; John A Foekens; Marcel Smid; John W M Martens; Michelle Echevarria; Vidya Kamath; Ji-Hyun Lee; Eleanor E Harris; Jonas Bergh; Javier F Torres-Roca Journal: Clin Cancer Res Date: 2012-07-25 Impact factor: 12.531
Authors: Tobin Strom; Sarah E Hoffe; William Fulp; Jessica Frakes; Domenico Coppola; Gregory M Springett; Mokenge P Malafa; Cynthia L Harris; Steven A Eschrich; Javier F Torres-Roca; Ravi Shridhar Journal: Radiother Oncol Date: 2015-07-30 Impact factor: 6.280
Authors: Jacob G Scott; Geoff Sedor; Jessica A Scarborough; Michael W Kattan; Jeffrey Peacock; G Daniel Grass; Eric A Mellon; Ram Thapa; Michael Schell; Anthony Waller; Sean Poppen; George Andl; Jamie K Teer; Steven A Eschrich; Thomas J Dilling; William S Dalton; Louis B Harrison; Tim Fox; Javier F Torres-Roca Journal: J Thorac Oncol Date: 2020-12-08 Impact factor: 15.609
Authors: Daniel E Oliver; Vernon K Sondak; Tobin Strom; Jonathan S Zager; Arash O Naghavi; Amod Sarnaik; Jane L Messina; Jimmy J Caudell; Andy M Trotti; Javier F Torres-Roca; Nikhil I Khushalani; Louis B Harrison Journal: Melanoma Manag Date: 2018-04-09
Authors: M Majem; J L Manzano; I Marquez-Rodas; K Mujika; E Muñoz-Couselo; E Pérez-Ruiz; L de la Cruz-Merino; E Espinosa; M Gonzalez-Cao; A Berrocal Journal: Clin Transl Oncol Date: 2021-03-02 Impact factor: 3.405